Ligand Pharmaceuticals’ Post

Alentis Therapeutics is moving forward with new clinical advancements!   Our portfolio company today announced the first patient dosed in a Phase 2 clinical trial of lixudebart (formerly named ALE.F02), a Claudin-1 targeting investigational antibody for the treatment of organ fibrosis.   The study evaluates the drug’s safety, tolerability, pharmacokinetics, and how well it protects against the loss of kidney function in patients with Antineutrophil Cytoplasmic Antibody (ANCA) associated vasculitis with Rapidly Progressive Glomerulonephritis (RPGN).   It is the second clinical trial investigating lixudebart in patients after the initiation of a clinical study in advanced liver fibrosis patients earlier this year.   Read more 👉 https://lnkd.in/eiHUTCnE   #fasterforthepatient #clinicalstudy #fibrosis #biopharma

Mission Therapeutics raises £25.2 million to accelerate its #mitophagy targeting lead drug candidates, #MTX325 and #MTX652, through clinical trials. The financing was jointly led by existing investors Pfizer, Sofinnova Partners, Roche, SR One Capital Management, IP Group plc, and Rosetta Capital Both MTX325 and MTX652 inhibit #USP30, a deubiquitylating enzyme (DUB) that constantly removes ubiquitin from mitochondria, limiting the removal of dysfunctional mitochondria. MTX325, a CNS penetrant which is a potential disease-modifying treatment for #Parkinson’s Disease, is about to enter Phase I trials; while peripherally-restricted MTX652 is currently in Phase II investigating cardiac surgery-associated kidney injury. Learn more about MTX325 and MTX652 using the link in the comments below. #DUBinhibitors #parkinsonsdisease #acutekidneyinjury #AKI

Lexeo Therapeutics Presents Interim Results from P-I/II Study of LX2006 for Treating Friedreich Ataxia Cardiomyopathy #lexeotherapeutics #LX2006 #friedreichataxia #cardiomyopathy #clinicaltrial #safety #efficacy #troponinI

Since 2018, Denali Therapeutics and Sanofi have collaborated on developing medications for neurological and autoimmune diseases, focusing on small compounds targeting the protein RIPK1. The partnership involved an upfront payment of $125 million. One outcome of this collaboration is SAR443820 or DNL788, a drug for amyotrophic lateral sclerosis (ALS), a rare neurological condition causing neuron degeneration and paralysis. Sanofi's recent earnings report indicates plans to advance DNL788 into Phase 3 trials later this year, based on positive Phase 2 results. This decision underscores the potential of the drug in treating ALS. #denali #Sanofi #ALS #medication #lifesciences

The Skyscraper-06 press release highlights concerns about combining anti-TIGIT ICIs with anti-PD-1/PD-L1 therapies, showing a cumulative negative effect (PD-L1 + Tirag + chemo, OS HR=1.33, PFS HR=1.27). Anti-TIGIT clinical trials show varied outcomes on primary endpoints. In mouse models, standalone anti-TIGIT mAbs are insufficient against subcutaneous tumors, necessitating combination therapies with PD-1 inhibitors. Regarding ICI combinations, I see two approaches: 1. The null model of drug independence suggests ICIs provide multiple opportunities for monotherapy response (not additive or synergistic), which hasn't been demonstrated effectively in anti-TIGIT studies. Combination outcomes range from mixed to cumulatively negative effects. 2. Alternatively, evaluating the Chemotherapy + anti-PD-L1 + anti-TIGIT combination in molecularly defined patient subsets remains crucial and unexplored. Most trials lean towards approach 1) for anti-TIGIT, despite the disappointing outcomes of SKYSCRAPER studies with tiragolumab. Do you think another anti-TIGIT could succeed where tiragolumab failed? Drug development is challenging. What are your thoughts on anti-TIGIT therapies? Press Release: https://lnkd.in/ggpgbRZA #Skyscraper06 #AntiTIGIT #PDL1 #ImmunoOncology

Dianthus Therapeutics presented promising preclinical data for its autoimmune drug candidate, DNTH103, in models of myasthenia gravis and chronic inflammatory demyelinating polyradiculoneuropathy. The drug showed significant reductions in fatigue index for myasthenia gravis patients and restored neuronal conduction velocity in CIDP patients. DNTH103 targets the complement pathway with a selective mechanism of action to potentially lower the risk of infections compared to current treatment options. Dianthus is actively progressing with clinical trials for DNTH103, with Phase 2 trials underway and FDA clearance obtained for further studies in related conditions. #autoimmune #preclinicaldata #DNTH103 #neurologicaldisorders #clinicaltrials Read more here: https://lnkd.in/ehrVMURB BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

Halia Therapeutics, Inc.'s and Biolexis Therapeutics, Inc.'s partnership have identified a novel brain-penetrant small molecule candidate targeting NLRP3-driven neuroinflammation by leveraging Biolexis’ MolecuLern™ AI-enabled approach. This milestone represents a significant advancement in treatments for neuroinflammatory disorders, including Parkinson’s. #HaliaTherapeutics #BiolexisTherapeutics #BioUtah #UtahLifeSciences https://ow.ly/Jqow50SSyf2

We are pleased to share Medicenna President and CEO Fahar Merchant's presentation of the Company's clinical updates on MDNA11 at the Oncology Innovation Forum last month, ahead of the American Society of Clinical Oncology 2024 Meeting. MDNA11, being evaluated in the Phase 1/2 ABILITY-1 Study, is the only non-alpha beta-enhanced IL-2 immunotherapy in clinical development. MDNA11 continues to demonstrate its best-in-class potential with differentiated deep and durable single agent activity in patients with advanced solid tumors who have failed checkpoint therapy. Sachs Associates video below accompanies the presentation on MDNA11. Read the full release for more information: https://lnkd.in/dR44hYaW #Immunotherapy #Oncology #Biotech #ClinicalTrial #AdvancedTumors

$MDNAF $MDNA.to We expect to provide a comprehensive data-set on monotherapy from MDNA11 dose-expansion trial And some topline data on combo trial with #Ketruda Finally Sachs shared another great presentation by Dr. Fahar, MDNA's CEO at the 10th Annual Oncology Innovation Forum!

Belzutifan, an inhibitor targeting hypoxia-induced factor-2 alpha (HIF-2α), was originally discovered by Peloton Therapeutics and subsequently developed by MSD. Its FDA approval in 2021 marked a significant milestone in the treatment of VHL-associated renal cell carcinoma. The increasing demand for bulk production of the therapeutic agent has spurred scientists to refine its synthesis through three distinct generations, including the supply route, filed commercial route, and green/sustainable route. The iterative process has not only enhanced the overall yields but also reduced the process mass index (PMI), which is a crucial matric indicating the greenness and sustainability of the synthesis process. Please click this link to review the three generations of synthesis. https://lnkd.in/eZ66vDSX #organicchemistry #medicinalchemistry #drugs #processchemistry #processdevelopment #belzutifan #HIF